Dysbiosis is a hallmark of atopic dermatitis (AD). The composition of skin microbiome communities and the causality of dysbiosis in eczema have not been well established. The objective of this review is to describe the skin microbiome profile in AD and address whether there is a causal relationship between dysbiosis and AD. The protocol is registered in PROSPERO (CRD42016035813). We searched PubMed, Embase, Scopus and ClinicalTrials.gov for primary research studies applying culture-independent analysis on the microbiome on AD skin of humans and animal models. Two authors independently screened the full text of studies for eligibility and assessed risk of bias. Because of heterogeneity no quantitative synthesis was done. Of 5735 texts, 32 met the inclusion criteria (17 published: 11 human and six animal studies). The studies varied in quality and applied different methodology. The skin in AD had low bacterial diversity (lowest at dermatitis-involved sites) and three studies showed depletion of Malassezia spp. and high non-Malassezia fungal diversity. The relative abundance of Staphylococcus aureus and Staphylococcus epidermidis were elevated and other genera were reduced, including Propionibacterium. A mouse study indicated that dysbiosis is a driving factor in eczema pathogenesis. The data are not sufficiently robust for good characterization; however, dysbiosis in AD not only implicates Staphylococcus spp., but also microbes such as Propionibacterium and Malassezia. A causal role of dysbiosis in eczema in mice should encourage future studies to investigate if this also applies to humans. Other important aspects are temporal dynamics and the influence of methodology on microbiome data.
Summary
Dysbiosis is a hallmark of atopic dermatitis (AD). The composition of skin microbiome communities and the causality of dysbiosis in eczema have not been well established. The objective of this review is to describe the skin microbiome profile in AD and address whether there is a causal relationship between dysbiosis and AD. The protocol is registered in PROSPERO (CRD42016035813). We searched PubMed, Embase, Scopus and ClinicalTrials.gov for primary research studies applying culture-independent analysis on the microbiome on AD skin of humans and animal models. Two authors independently screened the full text of studies for eligibility and assessed risk of bias. Because of heterogeneity no quantitative synthesis was done. Of 5735 texts, 32 met the inclusion criteria (17 published: 11 human and six animal studies). The studies varied in quality and applied different methodology. The skin in AD had low bacterial diversity (lowest at dermatitis-involved sites) and three studies showed depletion of Malassezia spp. and high non-Malassezia fungal diversity. The relative abundance of Staphylococcus aureus and Staphylococcus epidermidis were elevated and other genera were reduced, including Propionibacterium. A mouse study indicated that dysbiosis is a driving factor in eczema pathogenesis. The data are not sufficiently robust for good characterization; however, dysbiosis in AD not only implicates Staphylococcus spp., but also microbes such as Propionibacterium and Malassezia. A causal role of dysbiosis in eczema in mice should encourage future studies to investigate if this also applies to humans. Other important aspects are temporal dynamics and the influence of methodology on microbiome data.
What's already known about this topic?
• Dysbiosis is a hallmark of atopic dermatitis (AD): Staphylococcus aureus colonization is frequent and affects disease severity adversely.
• Recent availability of culture-independent methods to profile microorganisms has enabled studies of whole microbial communities and their role in dermatitis.
What does this study add?
• AD skin has low bacterial diversity, high non-Malassezia fungal diversity, high abundance of S. aureus and Staphylococcus epidermidis and reduced abundances of other genera.
• An animal study indicates that dysbiosis is a driving factor in eczema.
• More data are warranted for better characterization of the role of the microbiome in AD and the influence of methodological approaches needs to be resolved.
Recent availability of culture-independent methods to profile microorganisms and study microbial communities has increased our understanding of the microbiome and its impact in health and disease. Much research has focused on the gut microbiome, where findings demonstrate associations between dysbiosis and diseases such as diabetes and asthma. 1 The number of skin microbiome studies is rising. The skin is composed of a variety of niches selecting for colonization by specific microorganisms. 2 Host factors, for example sex, age and environmental exposures, [3] [4] [5] [6] also affect the niches and microbiome communities and it is becoming increasingly apparent that the skin microbiome, in turn, influences vital functions in the host, such as immunity and colonization by pathogenic microorganisms. 5 Atopic dermatitis (AD) is a chronic skin disease affecting up to 20% of children; it is less prevalent in adults. 7 Depending on age, it manifests at different sites with dry, itchy skin and relapsing eczema: in infants the cheeks are typically the first place to be affected, in toddlers it is the extensor aspects of joints, in older children it is flexure aspects of joints, and it has a varied presentation in adults. AD is characterized by immune dysregulation predisposing to IgE production. 8 Conventional culture-based work has established that dysbiosis is also a hallmark: 9 70% of lesional and 39% of nonlesional skin sites are colonized by Staphylococcus aureus, 10 which adversely affects disease severity. Fungi are also implicated. 11 Conventional culturing fails to grow about 80% of bacterial species.
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By applying culture-independent molecular methodology, dysbiosis is broadly described and the relative amount of present microbes becomes evident, which is also true for microbes not present. Although skin dysbiosis and the microbiome are anticipated to have an important role in the development of treatments, there has been no systematic review of the skin microbiome profile in AD. AD is a multifactorial disease, but the gene-environment interactions leading to the development of AD are not fully understood. Controversy remains with regard to distinguishing between primary events leading to AD and secondary events resulting from AD. 13 Whether the skin microbiome is a primary factor in AD pathogenesis is uncertain. This systematic review provides an overview of the AD skin microbiome profile. It is questioned if causal relationships between the skin microbiota and disease exist. To elaborate on this, animal studies are also included and the effect of treatment of AD on the microbiome is evaluated. A discussion of future directions in AD microbiome research is included.
Materials and methods
Complete literature search methods, risk of bias and data extraction were specified in advance and documented in a protocol registered in PROSPERO (CRD42016035813).
A systematic literature search, conducted on 21 October 2016, was performed in PubMed, Embase, Scopus and ClinicalTrials.gov using search terms from the categories 'skin', 'microbiome' and 'AD' -without language or date limitations. After an initial screen of titles and abstracts, two authors independently screened full texts for eligibility. Primary research studies (observational and interventional) were included if they applied culture-independent methods and whole-community analyses to characterize the AD skin microbiome of humans and animal models. Studies were excluded if they did not present data, included an incorrect study population, investigated the microbiome of other body sites or investigated selected microbial taxonomic units. Duplicate studies were excluded. Disagreements on eligibility were resolved by contacting the authors of the original studies.
Two authors assessed the risk of bias. For human studies we used the Cochrane Collaboration's tool for randomized controlled trials (RCTs) and adjusted Newcastle-Ottawa Scales for analytical nonrandomized case-control studies and cohort studies without a control group. For the animal studies we used adjusted versions of the Systematic Review Centre for Laboratory Animal Experimentation's (SYRCLE) risk-of-bias tool. 14 The highest-quality evidence received the greatest emphasis.
Two authors collected study characteristics and relative abundances of microbial taxonomic units (when > 1% and significant differences were found compared with a reference).
The criteria for study inclusion allowed for heterogeneity in study population, design and methods; therefore, no quantitative synthesis was carried out.
Results
In total, 5735 studies were identified ( Fig. 1 ). After review of the titles and abstracts, the full texts of 90 were screened. Based on the selection criteria, 32 records were included -17 were published (Table S1 ; see Supporting Information) and 15 were ongoing (Table S2 ; see Supporting Information). The published studies were examined in the most detail.
Human studies

Study description
Eleven human studies were identified (Table S1 ; see Supporting Information): two RCTs, seven case-control studies and two cohort studies. The studies included 355 patients with AD. Oh et al. also included patients with primary immunodeficiencies (n = 41), characterized by AD-like eczema. 15 Their data were regarded to be from an AD population. The age of the participants ranged from 2 months to 62 years and both sexes were included in 10 of the 11 studies. [15] [16] [17] [18] [19] [20] [21] [22] AD was clinically characterized by SCOring of Atopic Dermatitis (SCORAD) in eight of the studies; [15] [16] [17] [18] [19] [21] [22] [23] Eczema Area and Severity Index in one; 24 and Rajka and Langeland in one. 4 Patients with mild AD were included in two studies; 16, 20 moderate AD in nine; 4, [15] [16] [17] [18] [19] [20] 23, 24 and patients with severe AD in seven. 4, [15] [16] [17] 19, 20, 24, 25 Only one study distinguished microbiome composition according to disease severity. 20 The skin microbiomes of anatomically defined skin area(s) were investigated in nine of the 11 studies. 4, 15, 17, [19] [20] [21] 23, 25 Other studies compared affected with nonaffected skin sites. 4, 16, 18, 23, 24 Well-defined criteria for treatment allowed before and during the studies were provided in 10 of the 11 studies. 23 The fungal microbiome was characterized in two studies, 15, 20 using either the internal transcriber spacer sequence and 18S rDNA as targets for amplification, 15 or the D1/D2 
Risk of bias
The quality of the human studies varied (Table S3 ; see Supporting Information). We rated them as very good [score of 9; one RCT was rated low with regard to risk of bias (n = 4)], good (score 7-8; n = 4), fair (total score 5; n = 2) and poor (a poorly reported RCT; n = 1). The main reason for downgrading the quality of the 'fair' studies was either lack of information on cases and controls, 20 or missing a proper, nonexposed control population. 18 Atopic dermatitis skin microbiome profile
Staphylococcus aureus was abundant on AD skin compared with control skin, 4, 15, 19 and correlated positively to disease severity (Table S4 ; see Supporting Information). 15 Affected skin sites were dominated more by S. aureus than unaffected sites, 4, 15, 16, 26 especially inflamed areas (vs. xerotic) 16 -and during a flare the abundance increased dramatically in untreated patients. 19 Besides S. aureus, other species from the Staphylococcus genus were increased on involved sites. 24 These included S. epidermidis and S. haemolyticus. 15, 19, 26 The bacterial diversity on AD skin was low compared with control skin, 15, 19 and reduced during a flare. 19 Reductions in species from the genera Streptococcus, Propionibacterium, 4 Acinetobacter, Corynebacterium and Prevotella were found -not solely attributed to an increase in S. aureus. 19 Propionibacterium acnes was also found less frequently on facial AD skin than on control skin, 17 and was inversely correlated to disease severity. 15 Interestingly, although Corynebacterium decreased during AD flares, 19 it was increased in the antecubital flexure of patients with primary immunodeficiency. 15 After a flare, the species that were reduced increased in relative abundance. 19 The fungal microbiome showed, overall, that patients with AD had depleted numbers of Malassezia spp. 25 but enrichment of M. dermatis and more diverse non-Malassezia spp. than healthy controls. 15, 20, 25 These included Aspergillus, 15 Candida albicans and
Cryptococcus diffluens.
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Effect of treatment on the skin microbiome in atopic dermatitis
Compared with no treatment, intermittent treatment decreased the predominance of S. aureus and loss of bacterial diversity during a flare (Table S3 ; see Supporting Information), 19 with no improvement in SCORAD (data in original paper by Kong et al.) . 19 In contrast, Oh et al. found no such treatment-associated shifts in bacterial community diversity.
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One study evaluated the effect of dilute bleach baths and found that 10 days of baths improved SCORAD and number of lesional sites colonized by S. aureus. 16 Another study evaluated the effect of topical corticosteroid treatment alone or in combination with dilute bleach baths. Both treatments improved the clinical eczema representation and suppressed Staphylococcus spp. on lesional and nonlesional sites, with the authors concluding that there was no effect of the additional dilute bleach baths. 24 Emollient usage improved SCORAD and resulted in minor changes in the microbiome: 28 days of emollient use did not induce changes in the genus-level microflora at unknown skin site(s), but S. aureus increased in the nonemollient control group. 21 Eighty-four days of emollient use on affected and unaffected sites improved SCORAD in 26 of 36 individuals. 26 These 26 individuals had less relative abundance of Staphylococcus spp. and significantly more Stenotrophomonas, which also was inversely correlated to disease severity. 15 However, Stenotrophomonas maltophilia was found in the facial skin of patients with AD but not in controls. 17 Association between dysbiosis and atopic dermatitis Two-month-old infants who were later diagnosed with AD and had affected skin at the age of 12 months demonstrated a significantly lower number of commensal Staphylococcus spp. in their antecubital fossae than children with unaffected skin at the age of 12 months. 22 These data suggest that cutaneous dysbiosis might play a role in initiation of AD and that exposure to commensal staphylococci during early infancy might be important.
Animal studies
We included six animal studies (four noninterventional, two interventional), either with dogs with AD or mouse models (Table S1 ; see Supporting Information). Four studies sampled the skin by swabbing and two by biopsies. [27] [28] [29] [30] [31] [32] Different DNA extraction protocols were used. The bacterial microbiome was analysed in five of the six studies by 16S rRNA sequencing. 27, [29] [30] [31] [32] The fungal microbiome was characterized in one study. 28 No information on the number of PCR amplification cycles were given in four of the six studies. [27] [28] [29] [30] Relative abundances of microbial taxonomic units were provided in percentages in three of the studies, 27 The animal studies were mostly unclear with regard to risk of bias due to poor reporting (Table S3 ; see Supporting Information), which is common for animal studies. 14 
Animal atopic dermatitis skin microbiome profile and effect of treatment
Like humans, dogs with AD and Adam17-deficient mice had decreased bacterial diversity; 27, 29, 33 increased abundance of Staphylococcus spp.; 29 and S. aureus at the onset of eczematous inflammation (Table S5 ; see Supporting Information). 33 Corynebacterium spp. were also found to be increased. 29, 31, 33 Antimicrobial treatment of dogs presenting AD lesions decreased the clinical eczema score and reduced transepidermal water loss (TEWL). 29 No difference was found in skin pH. Furthermore, bacterial diversity normalized with decreased relative abundance of Staphylococcus spp.
Causality between dysbiosis and atopic dermatitis
In Adam17-deficient mice a prescreening of microbial composition was used to target systemic antimicrobial therapy. 33 Therapy resulted in decreased clinical scores and TEWL along with decreased relative abundance of the targeted species, S. aureus and Corynebacterium bovis, and increased bacterial diversity. Withdrawal of treatment dissipated the improvements in diversity. Eczema and dysbiosis reappeared after 2 weeks, as shown in a crossover design, where systemic antibiotics were shown to protect the Adam17-deficent mice from developing eczema and losing microbiome diversity. These data suggest a causal relationship between dysbiosis and AD in an animal model.
Discussion
In this systematic review we have demonstrated that AD skin in humans is characterized by low bacterial diversity and high non-Malassezia fungal diversity. On involved skin the bacterial diversity is even lower. The relative abundance of both S. aureus and S. epidermidis is elevated and the abundance of Propionibacterium is reduced, along with other genera (Streptococcus, Acinetobacter, Corynebacterium and Prevotella). A birth cohort study indicated that the absence of early colonization with commensal staphylococci might precede AD presentation, and an animal study indicated that dysbiosis was a driving factor in the pathogenesis of eczema. In interpreting these data, it should be emphasized that they were drawn from few studies with substantial heterogeneity and varied quality. Many of the included studies (15 of 17) analysed the microbiome using 16S rRNA sequencing, and even though the 16S rRNA gene is widely accepted as a biological fingerprint for bacterial species, there are some limitations. Some bacterial species have multiple copies of 16S rRNA genes, which may lead to an artificial over-representation in the data. 34 In addition, technical aspects may also introduce uncertainty; these include sampling technique, DNA extraction and sequencing protocol. [35] [36] [37] For instance classification accuracy varies with the specific region of the 16S rRNA gene chosen to be sequenced. 37 The limitations to 16S surveys have made the newer approach of whole-metagenome shotgun sequencing attractive. This method allows for analysis of the entire gene content of the microbial population, catch most species and may sequence deeply enough to identify strains. 37 This is crucial when it comes to understanding the physiological implications of a modified microbiome. Only one of 17 studies applied this method. Sequences obtained have short read lengths and many have no representation within databases. Therefore the different methodologies applied in the included studies likely affect outcome in microbiome composition and underline the importance of transparency in methodological approach. Not all of the included studies provided enough information on each methodological step. This shows a need for guidelines on good reporting of microbiome studies. A common criticism of using DNA-based technology to identify microbial communities is that DNA from dead and viable microorganisms are not distinguished. In the future, attempts to reduce DNA from dead microorganisms or performing RNA (cDNA)-based community analysis may help to minimize the detection of dead microorganisms. Such approaches would also contribute to the enlightenment of potential interplays and communication between hosts and the microbiome, for example in processes such as eczematous inflammation. Studies are moving from describing the microbiome to focusing on interactions by implicating RNA, protein and/or metabolite data. A study by Fyhrquist et al. showed a positive correlation between the relative abundance of skin Acinetobacter spp. and expression of anti-inflammatory molecules among healthy subjects, which was not present in atopic individuals. 38 In the study by Kong et al., 19 the relative abundance of Acinetobacter increased postflare, which supports a potential anti-inflammatory role of Acinetobacter in AD. Ongoing studies are investigating the effect of age and treatment of AD (Table S2 ; see Supporting Information). The finding of Corynebacterium being reduced in AD flares but increased in the antecubital flexure of patients with primary immunodeficiency suggest that underlying genetics may affect the microbiome. Mutations in the gene encoding the protein filament aggregating protein (filaggrin) leading to a functional absence of the protein predisposes individuals to developing atopic eczema, an increase in stratum corneum pH, and an increase in susceptibility to recurrent bacterial skin infection among patients with AD. [39] [40] [41] Filaggrin deficiency in ichthyosis vulgaris is associated with a low abundance of proteolytic Grampositive anaerobic cocci, which are shown to be better at inducing expression of antimicrobial peptides in cultured keratinocytes. 42 This could be a mechanism favouring the growth of S. aureus or infection. A trend for lower bacterial diversity in one control and two AD filaggrin-null mutation subjects was seen in the study by Chng et al. 25 However, the role of filaggrin on the skin microbiome in AD is not known and none of the studies included in this review could elaborate thoroughly on this.
In line with the S. aureus data presented in this review, a recent meta-analysis showed that patients with AD were more likely to be colonized with S. aureus than healthy controls, with higher odds ratios (OR) for lesional skin [OR 19Á74, 95% confidence interval (CI) 10Á88-35Á81] than for nonlesional skin (OR 7Á77, 95% CI 3Á82-15Á82). 10 With S. aureus being more abundant on nonlesional skin, this suggests that the skin is susceptible to pathogen colonization and at risk of progressing toward a diseased state. This indicates that antistaphylococcal treatment could be beneficial. However, a systematic review by Bath-Hextall et al. showed that reducing the number of S. aureus in people with uninfected eczema did not result in reduced disease activity. 43 Targeting specific S. aureus strains could potentially improve the outcome of antistaphylococcal treatment. This is supported by the finding of a single nucleotide polymorphism in a staphylococcal lipase gene being preferentially hosted in AD. 25 However, targeting other bacteria might also be beneficial. An idea of a critical window early in life during which exposure to certain microbes is important for the development of the immune system and allergic diseases has arisen and is supported by studies showing reduced microbial diversity in the gut before the development of atopy. 1, 44, 45 Further, tolerance to the skin commensal S. epidermidis is preferentially established in neonatal life in mice. 46 Current data are limited and it is difficult to evaluate whether the cutaneous microbiome plays a role in the initiation of AD. 22 By hypothesizing that dysbiosis precedes AD flares and severity, studies are currently investigating prevention and treatment targeting dysbiosis. Moisturizers are key in AD management, to restore and preserve skin barrier integrity. One RCT showed that emollient therapy from birth in babies at high risk of AD enhanced the skin barrier and reduced the relative risk of AD incidence by 50% after 6 months. 47 An ongoing study by Glatz (Table S2; see Support- ing Information) is investigating if shifts in the skin microbiome are associated with this improvement. Preliminary data show that preventative emollient usage lowers pH, does not change TEWL and increases the number of bacterial taxonomic units and Streptococcus spp. 48 As Streptococcus was reduced during flares but increased in the abscense of commensal staphylococci in infants before AD presentation, 19, 22 future studies should investigate the role of Streptococci spp. in AD. Stenotrophomonas spp. may also have an important role in restoration of the skin microbiome. 18 Another approach to manipulating the skin microbiome is by adding beneficial bacteria to moisturizers. One RCT showed that cream containing 5% lysate of the nonpathogenic Proteobacteria Vitreoscilla filiformis significantly improved SCORAD, TEWL, the patient's assessment of itch and loss of sleep compared with placebo. 49, 50 Ongoing studies by Gallo and colleagues apply the same principle (Table S2 ; see Supporting Information): in an attempt to decrease S. aureus colonization in AD skin, they are isolating beneficial Staphylococcal species from the patients themselves and placing them in a moisturizer and applying the moisturizer to the subjects' own arms.
To utilize the microbiome in prevention and treatment strategies of AD, more data from human studies are needed on the skin microbiome dynamics related to clinical measures, temporal resolution and how different factors modify the microbial abundances to be able to predict responses in the microbiome to perturbations. Good speciation and strain-level identification in combination with RNA, protein and metabolite data would strengthen such data and provide valuable insights.
While the microbiome is increasingly drawing attention as a possible target in the prevention and treatment of AD, new methodological approaches have not yet brought us far in understanding the impact of dysbiosis in AD. Staphylococcal species are key players in worsening of AD, and may also be important in the establishment of the disease. Other microbes such as Propionibacterium, Streptococcus, Acinetobacter and Malassezia have been found to be implicated in AD dysbiosis. However, robust data are missing on the influence of methodological procedures, characteristics of the microbiome structure related to temporal dynamics, clinical measures and factors altering the microbiome.
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